// App-Quantinova.ai

BSH2020‐PO‐203 : Defibrotide treatment for veno‐occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: outcomes by severity and multi‐organ failure status in an observational registry study

Researchers

Presenter

  • S. Lawson

Principal Investigators

  • M. Lisa Battista

  • D. Blaise

  • E. Calore

  • S. Cesaro

  • N. Maximova

  • K. Perruccio

  • R. Wynn

  • M. Zecca

  • M. Labopin

  • V. Amber

  • R. J. Ryan

  • M. Mohty

Medical Centers

  • Birmingham Children's Hospital, Birmingham, United Kingdom

  • Rheumatology Clinic, University of Udine, Udine, Italy

  • Institut Paoli-Calmettes, Marseille, France

  • The Clinic of Pediatric Hematology–Oncology, University Hospital of Padova, Padua, Italy

  • Pediatric Hematology‐Oncology, “Ospedale della Donna e del Bambino”, Verona

  • Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy

  • Pediatric Oncology and Hematology Section, Santa Maria della Misericordia Hospital, Perugia, Italy,

  • Royal Manchester Children's Hospital, Manchester, United Kingdom

  • Paediatric Haematology / Oncology, Fondazione IRCCS, Policlinico San Matteo Foundation, Pavia, Italy,

  • Hôpital St Antoine, Sorbonne University, INSERM UMRs 938, Paris, France

  • Jazz Pharmaceuticals, Oxford

  • Jazz Pharmaceuticals, Inc., Philadelphia, PA

Locations

  • United Kingdom

  • Italy

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Hepatic veno-occlusive disease with immunodeficiency

Biomarkers

  • Hematocrit

Drug/Treatment

  • Defibrotide

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT03032016

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved